OX-40 Receptor Agonist Therapeutics - Pipeline Analysis 2017

1
OX-40 Receptor Emerging as a Novel Target in
Cancer Immunotherapy
2
OX-40 Receptor Agonist Therapeutics
OX-40 receptor agonist therapeutics pipeline in
2017
The study analyzed that the OX-40 receptor
agonist therapeutics pipeline comprises
approximately nine drug candidates in different
stages of development. OX-40 is a costimulatory
receptor that binds to its only known ligand,
OX-40L, initiating cellular signaling events
required for full activation of T cells following
their recognition of a foreign antigen. OX-40
agonists mimic the effect of OX-40L, and boost
the OX-40 signaling, and thereby leads to the
suppression of the anti-tumor immune response in
cancer patients. OX-40 agonists in combination
with checkpoint immunotherapies, surgical
resection, and radiotherapy has demonstrated
promising results for the treatment of cancer
patients. Access Report Summary with Detailed TOC
on OX-40 Receptor Agonist Therapeutics Pipeline
Analysis, 2017 - Clinical Trials Results,
Patent, Designation, Collaboration, and Other
Developments at https//www.psmarketresearch.com
/market-analysis/ox40-receptor-agonist-therapeutic
s-pipeline
3
OX-40 Receptor Agonist Therapeutics
Insights on procedure segments
According to the research findings, most of the
drug candidates of OX-40 receptor agonist
therapeutics pipeline are being developed as a
monoclonal antibody.
Maximum drugs being developed as monoclonal
antibody
Most of the companies are focused on developing
their drug candidates as monoclonal antibodies in
the OX-40 receptor agonist therapeutics pipeline.
Monoclonal antibodies are homogenous and
consistent. Also, they can be renewably generated
once a suitable hybridoma is developed and are
highly sensitive to small changes in both salt
concentration and ph.
4
OX-40 Receptor Agonist Therapeutics
Various collaborations for OX-40 receptor agonist
drug development
In November 2015, GlaxoSmithKline plc and Merck
Co., Inc. entered into a collaboration to
initiate the Phase I clinical trial designed to
evaluate GSK3174998 as monotherapy in combination
with Mercks anti-PD-1 therapy, Keytruda
(pembrolizumab). Some of the key players
developing drugs as OX-40 receptor agonist for
the treatment of various indications include
MedImmune, LLC, Agenus Inc., Pfizer Inc.,
GlaxoSmithKline plc and others.
5
OX-40 Receptor Agonist Therapeutics
Download report sample at
https//www.psmarketresearch.com/market-analysis/o
x40-receptor-agonist-therapeutics-pipeline/report-
sample
6
GET IN TOUCH
THANK YOU!
For information regarding permissions and other
queries Kindly write to
US/Canada Toll-Free 1-888-778-7886